Purpose To date, there is no effective therapy for triplenegative breast cancer (TNBC), which has a dismal clinical outcome. Upregulation of tissue factor (TF) expression leads to increased patient morbidity and mortality in many solid tumor types, including TNBC. Our goal was to employ the Fab fragment of ALT-836, a chimeric anti-human TF mAb, for PET imaging of TNBC, which can be used to guide future TNBC therapy. Methods ALT-836-Fab was generated by enzymatic papain digestion. SDS-PAGE and FACS studies were performed to evaluate the integrity and TF binding affinity of ALT-836-Fab before NOTA conjugation and 64 Cu-labeling. Serial PET imaging and biodistribution studies were carried out to evaluate the tumor targeting efficacy and pharmacokinetics in the MDA-MB-231 TNBC model, which expresses high levels of TF on the tumor cells. Blocking studies, histological assessment, as well as RT-PCR were performed to confirm TF specificity of 64 Cu-NOTA-ALT-836-Fab. Results ALT-836-Fab was produced with high purity, which exhibited superb TF binding affinity and specificity. Serial PET imaging revealed rapid and persistent tumor uptake of 64 Cu-NOTA-ALT-836-Fab (5.1±0.5 %ID/g at 24 h postinjection; n=4) and high tumor/muscle ratio (7.0±1.2 at 24 h post-injection; n=4), several-fold higher than that of the blocking group and tumor models that do not express significant level of TF, which was confirmed by biodistribution studies. TF specificity of the tracer was also validated by histology and RT-PCR. Conclusion
Introduction
Triple-negative breast cancer (TNBC), that does not express estrogen receptor, progesterone receptor or human epidermal growth factor receptor 2, is among the most common types of breast cancer [1] . Almost 15 % of invasive breast cancers are diagnosed as TNBC, and there is no effective diagnosis method or treatment regimen due to the lack of targets for effective delivery of imaging probes and therapeutic agents [1, 2] . Most TNBC are characterized by aggressiveness, with early Sixiang Shi and Hao Hong contributed equally to this work. dissemination and a high risk of relapse [2] . TNBC tends to be associated with a poorer survival rate compared than other breast cancer types [3] . Therefore, the seeking of targets to boost diagnosis and treatment efficiency of TNBC has attracted tremendous interest from global researchers.
Tissue factor (TF), also known as platelet tissue factor, factor III, thrombokinase or CD142, has been confirmed to be abundantly present on TNBC cells (e.g. MDA-MB-231) [4, 5] . TF plays various important roles in cancer cell signaling, including the inhibition of apoptosis and promotion of cell migration [6] . Numerous animal and patient studies have shown the impact of TF on TNBC progression [7] [8] [9] . Importantly, the tumor TF expression level can serve as a prognostic index, since high TF expression level usually contributes to a decreased overall survival rate in TNBC patients [10, 11] . Based on the above-mentioned findings, TF could be adopted as a promising target for effective diagnosis and therapy of TNBC. To the best of our knowledge, TF has not been tested with in vivo targeting and imaging of TNBC to date.
ALT-836, a chimeric antihuman TF monoclonal antibody that binds to the factor X-binding site in TF with subnanomolar affinity [12, 13] , was used in this study for TF targeting. Recently, a phase 2 clinical trial using ALT-836 in acute lung injury and acute respiratory distress syndrome has been completed (Clinical Trials.gov Identifier NCT00879606), and the results indicate that ALT-836 is well tolerated and beneficial to the whole patient population. In addition, a clinical trial in which ALT-836 will be used against solid tumors with elevated TF levels has also been initiated (Clinical Trials.gov Identifier: NCT01325558).
PET imaging was applied in this study to examine the TF targeting of an ALT-836-based imaging agent in a mouse TNBC model. Although antibody-based imaging agents show optimal tumor accumulation, one of the major obstacles in PET imaging with an intact antibody is the prolonged circulation half-life [14] . The tumor uptake might not reach the peak until a few days after injection [12] . As alternatives, antibody fragments, which maintain the targeting specificity and show rapid blood clearance, have been utilized for PET imaging [15] [16] [17] [18] [19] . IgG type antibodies are typically composed of Fab and Fc, with Fab containing the antigen-binding sites [19] . The specificity of ALT-836-Fab for TF on TNBC cells was assessed in this study for potential application as an imaging agent for TNBC.
In this study,
64
Cu was introduced as a radiolabel for ALT-836-Fab via 1,4,7-triazacyclononane-1,4,7-triacetic acid (NO-TA). Various in vitro, in vivo, and ex vivo studies were performed to validate the expression of TF in the TNBC model and correlate the tumor uptake of Cu-NOTA-ALT-836-Fab showed rapid blood clearance and TF-specific tumor uptake.
Materials and methods

Chemicals
ALT-836 was provided by Altor Bioscience Corporation (Mira m a r, FL ) . S -2-(4-Isothiocyanatobenzyl)-1,4,7-triazacyclononane-1,4,7-triacetic acid (p-SCN-Bn-NOTA) was purchased from Macrocyclics, Inc. (Dallas, TX). Chelex 100 resin (50 -100 mesh) and fluorescein isothiocyanate (FITC) were acquired from Sigma-Aldrich (St. Louis, MO). Rat anti-mouse CD31 primary antibody was purchased from BD Biosciences (San Diego, CA). AlexaFluor488-labeled and Cy 3 -labeled secondary antibodies were purchased from Jackson Immunoresearch Laboratories, Inc. (West Grove, PA). PD-10 desalting columns were purchased from GE Healthcare (Piscataway, NJ). Cu was produced by a GE PETrace cyclotron using the 64 Ni(p,n) 64 Cu reaction, which has a specific activity of >5 Ci/μmol at the end of bombardment. Water and all buffers were of Millipore grade and pretreated with Chelex 100 resin to ensure that the aqueous solution was free of heavy metals. All other reaction buffers and chemicals were from Thermo Fisher Scientific.
Generation and characterization of ALT-836-Fab
The production of ALT-836-Fab was carried out by digestion of ALT-836 (5 mg/mL) by immobilized papain (papain/ALT-836 weight ratio 1:40) in a reaction buffer (20 mM sodium phosphate dibasic, 10 mM disodium ethylenediaminetetraacetic acid, and 80 mM L-cysteine hydrochloride) for 4 h at 37°C under constant stirring [15, 19] . Subsequently, the supernatant was collected and purified on a Sephadex G-75 size-exclusion column using phosphate-buffered saline (PBS) as the mobile phase. The eluate from the Sephadex G-75 size-exclusion column was examined by UV absorbance at 280 nm [20] . The purity of ALT-836-Fab was evaluated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE; 5 % stacking gel and 8 % resolving gel), which was run under nonreducing conditions and stained with Coomassie brilliant blue R-250 [21] .
Antibody fragment conjugation
ALT-836-Fab was reacted with p-SCN-Bn-NOTA or FITC in a similar buffer condition, at a molar ratio of 1:10 at pH 9.0 for 2 h [12] . The final products (NOTA-ALT-836-Fab or FITC-ALT-836-Fab) were purified on PD-10 size-exclusion columns with PBS as the mobile phase.
Cell lines and animal models
MDA-MB-231 (high TF expression) [22] [23] [24] [25] and MDA-MB-435 (low TF expression) [23] human breast carcinoma cell lines were both obtained from the American Type Culture Collection (ATCC, Manassas, VA) and cultured according to the supplier's instructions. Cells were used for in vitro and in vivo experiments when they reached about 80 % confluence. All animal studies were conducted under a protocol approved by the University of Wisconsin Institutional Animal Care and Use Committee. Female nude mice (Harlan, Indianapolis, IN) at 4 -5 weeks of age were each injected with 2× 10 6 MDA-MB-231 or MDA-MB-435 cells subcutaneously into the right flank. The tumor sizes were monitored daily and the mice were used for in vivo experiments when the tumor diameter had reached 5 -8 mm.
Flow cytometry
MDA-MB-231 and MDA-MB-435 cells were harvested and suspended in cold PBS with 2 % bovine serum albumin at a concentration of 5×10 6 cells/mL, incubated with FITC-ALT-836-Fab at different concentrations (1 μg/mL and 5 μg/mL) for 30 min at room temperature, centrifuged at 1,000 rpm for 5 min, and washed three times with cold PBS. Subsequently, the cells were analyzed using a BD FACSCalibur 4 color analysis cytometer (Becton-Dickinson, San Jose, CA) and FlowJo analysis software (Tree Star, Inc., Ashland, OR).
Radiolabeling
64
Cu was produced with an onsite cyclotron (GE PETrace). Cu-NOTA-ALT-836-Fab was purified by PD-10 size exclusion column chromatography, using PBS as the mobile phase. The radioactive fraction containing 64 Cu-NOTA-ALT-836-Fab was collected for further in vitro and in vivo studies.
PET imaging and biodistribution studies
At different time-points after injection (p.i.) of 5 -10 MBq of 64 Cu-NOTA-ALT-836-Fab via a tail vein, PET scans of MDA-MB-231 and MDA-MB-435 tumor-bearing mice (four mice per group) were carried out using a microPET/microCT Inveon rodent model scanner (Siemens Medical Solutions USA, Inc.). Data acquisition, image reconstruction, and region-of-interest (ROI) analysis of the PET data were performed as previously described [12, 19] . Briefly, the images were acquired by 10-min static PET scans and reconstructed using a maximum a posteriori algorithm, without attenuation or scatter correction. ROI analysis of each PET scan was carried out using software (Inveon Research Workplace, IRW) based on decay-corrected whole-body images, calculated with the injected dose measured by a dose calibrator (Capintec, Inc., Ramsey, NJ). Quantitative PET data of the tumor and major organs are presented as percentage injected dose per gram of tissue (%ID/g). After the last scan at 24 h p.i., biodistribution studies were performed to corroborate the PET data. Mice were sacrificed and tumor, blood and major organs/tissues were collected and wet-weighed. The radioactivity in the tissue was measured using a γ counter (PerkinElmer) and the results are presented as %ID/g (mean ±SD). To confirm the in vivo targeting specificity, a blocking test was also performed in MDA-MB-231 tumor-bearing mice after preinjection of 2 mg ALT-836 intact antibody.
Histology MDA-MB-231 and MDA-MB-435 tumor-bearing mice were sacrificed to collect positive and negative tumor sample, respectively. Liver, spleen and muscle were collected from MDA-MB-231 tumor-bearing mice as controls. Collected tissues were frozen and cryosectioned for histological analysis. Frozen tissue slices of 7 μm thickness were fixed with cold acetone and stained for endothelial marker CD31 using rat anti-mouse CD31 antibody as the primary antibody and Cy3-labeled donkey anti-rat IgG as the secondary antibody. To stain TF, the same tissue slices were also incubated with ALT-836 as the primary antibody and AlexaFluor488-labeled goat anti-human IgG as the secondary antibody. All images were acquired using a Nikon Eclipse Ti microscope.
Quantitative real-time RT-PCR
To confirm TF expression in both MDA-MB-231 and MDA-MB-435 tumors, quantitative real-time RT-PCR was performed. MDA-MB-231 and MDA-MB-435 tumor tissues were homogenized in an icy environment, and the total RNA was isolated using a Qiagen RNeasy Minikit (Qiagen Inc., Valencia, CA), reverse transcribed and amplified using a Qiagen OneStep RT-PCR kit. Real time PCR was performed with a Bio-Rad MyIQ detection system, using TaqMan primers for TF (Hs01076029_ml F3) and GAPDH (Mm99999915_g1 Gapdh; Applied Biosystems, Carlsbad, CA). The PCR product was run on 0.5 % agarose gel at 100 V for 1 h [26] .
Results
Generation and characterization of ALT-836-Fab ALT-836 was digested with papain in a reaction buffer at 37°C [19] . After papain digestion, ALT-836-Fab was separated from the reaction mixture through a Sephadex G-75 column (fractionation range 3,000 -80,000 Da) using PBS as the mobile phase. The elution profile was tested under a 280 nm UV spectrum (Fig. 1a) and elution faction from 17 to 18 mL (peak ALT-836-Fab concentration) was used in later experiments. The results acquired from SDS-PAGE suggested a molecular weight of 50 -55 kDa for ALT-836-Fab with high purity (Fig. 1b) .
In vitro TF targeting
Before in vivo studies, flow cytometry was performed to examine the targeting efficiency and specificity of ALT-836-Fab in vitro. After treatment with FITC-ALT-836-Fab at a low concentration (1 μg/mg), the fluorescence signal from MDA-MB-231 cells (TF-positive) was 25 times higher than that from the negative group, whereas the signal from MDA-MB-435 cells (TF-negative) was only 4 times higher (n=3; Fig. 2 ). This result clearly demonstrated the TF specificity of ALT-836-Fab. Cu-NOTA-ALT-836-Fab in TF-negative MDA-MB-435 tumor was significantly lower at all time-points examined (3.0±0.3%ID/g at 0.5 h p.i., and gradually decreasing with time: 2.6±0.3, 2.3± 0.5, 1.9±0.3, and 1.7±0.1 %ID/g at 3, 6, 16, and 24 h p.i., respectively; n=4; Figs. 3 and 4c) . Taken together, a significant enhancement of tumor uptake was achieved with ALT-836-Fab (2.7-fold higher than the blocking group and 3.0-fold higher than the negative group at 24 h p.i.), suggesting that ALT-836-Fab could specifically target TF in TNBC.
Due to the smaller size of the Fab fragment (50 -55 kDa) compared to the intact antibody (about 150 kDa), Fab could be cleared through both the hepatobiliary and renal pathways (Fig. 3) . The tracer accumulation in the liver and blood was similar in all three groups (MDA-MB-231, MDA-MB-231 with blocking, and MDA-MB-435; Fig. 4a-c Cu-NOTA-ALT-836-Fab (negative group). d Comparison of tumor/muscle ratios in the positive, blocking and negative groups. The differences in tumor uptake and tumor/muscle ratios among the three groups were statistically significant (P<0.05) at all time-points except 0.5 h. All data were obtained from four mice per group MDA-MB-231 group (tumor/muscle ratios 3.0±0.4, 3.9±0.5, 4.8±0.9, 7.0±0.8, and 7.0±1.2 at 0.5, 3, 6, 16, and 24 h p.i., respectively; n=4; Fig. 4d ) than in the blocking group (tumor/ muscle ratios 1.6±0.2, 1.8±0.5, 1.9±0.4, 2.2±0.2, and 2.2± 0.5 at 0.5, 3, 6, 16, and 24 h p.i., respectively; n=4) and the MDA-MB-435 group (tumor/muscle ratios 3.0±0.3, 2.2±0.5, 2.0±0.5, 2.5±0.6, and 2.2±0.2 at 0.5, 3, 6, 16, and 24 h p.i., respectively; n=4), highlighting the potential of ALT-836-Fab as a good contrast agent for TF delineation in TNBC.
After the last scan at 24 h p.i., mice were sacrificed for biodistribution studies to validate the ROI analysis of the PET images (Fig. 5) . The quantitative results based on biodistribution studies and ROI analysis matched very well, suggesting that ROI analysis of PET images accurately reflected the distribution of 64 Cu-NOTA-ALT-836-Fab in tumor-bearing mice.
Histology
Histological studies were performed to validate the expression levels of TF in positive and negative tumors (Fig. 6) . Red fluorescence indicated the expression of CD31, which represents the location of vasculature, whereas green fluorescence demonstrated the expression of TF, which is the target of ALT-836-Fab. In MDA-MB-231 tumors, a significantly high TF expression level was achieved, and the TF expression did not overlap with the location of vasculature. In MDA-MB-435 tumors, TF expression was relatively low. Taken together, the histology study further demonstrated the TF specificity of ALT-836-Fab.
Quantitative real-time RT-PCR
Real-time RT-PCR was applied to further confirm the TF expression levels in both MDA-MB-231 and MDA-MB-435 human breast carcinomas. The TF expression in MDA-MB-231 tumors (C T =21.7±0.2 min, where C T denotes critical time; n=3) was significantly higher than in the MDA-MB-435 tumors (C T =29.1±0.2 min; n=3), while the expression levels of the positive control GAPDH in both tumors were similar (C T ≈15.2±0.4 min; n=3; Fig. 7 ). DNA gel electrophoresis confirmed the real-time RT-PCR results (Fig. 7b) .
Discussion
There is no effective management for TNBC, which has a dismal clinical outcome [28] [29] [30] . To date, most studies on PET imaging of TNBC have been performed with 18 F-FDG [31] [32] [33] . Although conventional 18 F-FDG PET imaging has been proven to be useful for the detection of TNBC in vivo, poor specificity is a major concern that limits the application of 18 F-FDG in the clinical setting, since 18 F-FDG uptake represents only the metabolic level and does not provide information from tumors at the cellular/molecular levels. Therefore, the pursuit of novel targeting agents of TNBC is highly desired. Antibody/antibody fragment could function as alternative imaging probes for diagnosis and therapy of TNBC with superior specificity. TF has been found to be highly expressed in several human TNBC cell lines, including MDA-MB-231, MDA-MB-468, and HCC-1806 [34] . In this study, we achieved excellent TNBC imaging with 64 Cu-NO-TA-ALT-836-Fab in MDA-MB-231 TNBC xenografts. Since TF plays a critical role in cancer cell signaling for tumor growth and metastasis [6] , the inhibition of TF might open another window for effective treatment of TNBC in the future, which now has limited therapeutic options.
One of the most important advantages of the Fab fragment is its quick blood clearance. Compared with the full antibody which has a prolonged circulation half-life and high background, 64 Cu-ALT-836-Fab exhibited very low background signal as early as 0.5 h p.i. (about 2 %ID/g in blood and about1 %ID/g in muscle, Fig. 4a ). The quick blood clearance endows 64 Cu-ALT-836-Fab with superior tumor contrast, making it applicable to the imaging of other cancer types in organs with abundant blood flow, such as lung cancer. Antibody fragments can be cleared through both the hepatobiliary and renal pathways. The clearance varies with different Fab fragments, possibly dependent on their size, structure, and hydrophilicity. In this study, ALT-836-Fab was cleared predominantly by the liver, whereas other antibody fragments, such as TRC105-Fab and cetuximab-Fab, are mainly cleared by the kidney [19, 35] . Therefore, the type of Fab should be correctly selected for different cancers. The other advantage of Fab is the prompt tumor uptake, which would allow ALT-836-Fab to be translated into same-day immunoPET imaging in the clinical setting to improve TNBC patient management. Alternative short half-life isotopes (e.g. 61 Cu, 45 Ti, 44 Sc,
68
Ga) could also be used as the radiolabel for PET imaging with Fab. The limitation of Fab is lower binding avidity compared to the full antibody, since Fab has only one antigen-binding site. For example, the uptake in positive tumors (MDA-MB-231) was only 5.1 %ID/g in this study, which is about 3-fold higher than in negative tumors (MDA-MB-435) and about 2.5-fold higher than in blood. This might restrict the future application of Fab fragments in tumor imaging. If high absolute tumor uptake rather than high tumor contrast is required, Fab may not be very suitable [12] .
Radiolabeling stability is a common concern in PET imaging, since PET only detects the location of the radiolabel. We have demonstrated in previous studies that 64 Cu is very stably bound to NOTA, which is one of the best chelators for 64 Cu [27, 36] . NOTA-ALT-836-Fab is also easily applicable to 68 Ga labeling, which can potentially make the clinical translation much easier. We have also demonstrated that the conjugation of NOTA and radiolabeling did not affect the targeting efficiency and specificity of ALT-836 [12] . Therefore, the asdesigned imaging probe used in this study truly represented the TF expression in TNBC.
Conclusion
We report here the generation and characterization of ALT-836-Fab, and its use in PET imaging of TF expression in TNBC. Rapid, persistent, and TF-specific uptake of 64 Cu-NO-TA-ALT-836-Fab was achieved in MDA-MB-231 tumors. Because of quick blood clearance and tumor uptake, 64 Cu-NOTA-ALT-836-Fab could be potentially translated into same-day immunoPET imaging to improve patient management. Considering the current limited diagnosis and therapy options for TNBC, TF targeting and imaging could pave the way for effective delivery of imaging/therapy agents to TNBC.
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